Quick Takeaways: Why It Matters? Dechra has launched Laverdia (verdinexor tablets), the first and only FDA‑approved oral treatment for dogs with lymphoma, enabling at‑home therapy that can start on Day 1 after diagnosis. Canine lymphoma is one of the most common cancers i...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways: Why It Matters? MUMS status gives Masivet a clearer US regulatory and commercial path, adding potential 7‑year market exclusivity and grant support on top of its established European use, which should enhance the asset’s value as AB Science courts par...
